Active Substance: Lorazepam.
Overview
Welcome to Dwaey, specifically on ATIVAN 1mg page.
This medicine contains an important and useful components, as it consists of
Lorazepamis available in the market in concentration
Lorazepam
Patient w/ compromised pulmonary function (decreased reserve), myasthenia gravis, CV or cerebrovascular disease, impaired gag reflex; at risk of falls. Patient w/ history of alcohol or drug abuse and those w/ personality disorders. Not intended for treatment of primary depressive or psychotic disorders. It should not be administered by intra-arterial inj. Avoid abrupt withdrawal. Renal and mild to moderate hepatic impairment. Elderly or debilitated patients, childn. Pregnancy and lactation. Patient Counselling May impair ability to perform activities requiring mental alertness or physical coordination (e.g. driving, operating machinery) for 24-48 hr following admin of the drug. Monitoring Parameters Monitor resp and CV status, BP, heart rate, symptoms of anxiety, CBC and LFTs. Lactation: Excreted in human breast milk; not recommended
Anxiety, Status epilepticus, Sedation, psychosomatic, organic or psychotic illness, insomnia associated with anxiety, nervousness, restlessness, nausea and vomiting related to chemotherapy and anticonvulsants, and as a premedicant before dental or general surgery or prior to investigative procedures where there may be discomfort.
Severe hepatic impairment; respiratory depression; acute narrow-angle glaucoma; pregnancy and lactation.
Sedation, drowsiness, ataxia, dizziness, confusion, depression, unmasking of depression, hypotension, fatigue, muscle weakness, asthenia, transient anterograde amnesia or memory impairment, changes in vital signs (e.g. resp rate, BP). Thrombocytopenia, agranulocytosis, pancytopenia, hyponatraemia, disinhibition, euphoria, suicidal ideation, nausea, constipation, change in libido, impotence, decreased orgasm. Increase in bilirubin, liver transaminases or alkaline phosphatase. Potentially Fatal: Resp depression.
4
Lorazepam is a short acting benzodiazepine. It increases neuronal membrane permeability to Cl ions by binding to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron w/in the CNS (including the limbic system, reticular formation) and enhancing the GABA inhibitory effects resulting in hyperpolarisation and stabilisation.
Drugs that affect the CNS (e.g. barbiturates, phenothiazines, antidepressants, MAOIs) may have additive CNS effects. Scopolamine may increase sedation, hallucinations and irrational behaviour. May reduce sedative and anxiolytic effect w/ caffeine, theophylline or aminophylline. May increase plasma level w/ Na valproate or probenecid.
Information not available